ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
by Zacks Equity Research
BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its stellar performance.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Intuitive (ISRG) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Intuitive Surgical (ISRG) has been gaining from a series of positive developments of late.
Top Stock Reports for Walmart, Nike & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Nike, Inc. (NKE) and Citigroup Inc. (C).
Medtronic Displays All-Business-Line Growth Despite Cost Woes
by Zacks Equity Research
Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
Neogen's (NEOG) Food Safety Test Receives AOAC Clearance
by Zacks Equity Research
Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.
Bio-Rad's Blood Typing Market Growth Strong on New Products
by Zacks Equity Research
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.
Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients
by Zacks Equity Research
Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
NuVasive Gets FDA Nod for CoRoent Small Interlock System
by Zacks Equity Research
NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
Henry Schein to Showcase New Dental Offerings at GNYDM
by Zacks Equity Research
Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.
Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
by Zacks Equity Research
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Dexcom (DXCM) gains from several positive developments.
Myriad Genetics' Test Added in Disease Activity Measure List
by Zacks Equity Research
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
Hologic (HOLX) Set to Divest Medical Aesthetics Business
by Zacks Equity Research
Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.
Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman
by Zacks Equity Research
Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman
NUVA or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?
by Zacks Equity Research
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge
by Zacks Equity Research
The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.